Is NCT06138821 recruiting in Morgantown, WV?

Yes, NCT06138821 is currently recruiting participants at its Morgantown, WV location. This obesity clinical trial is actively enrolling qualified participants.

How do I join the obesity clinical trial in Morgantown?

To join this clinical trial in Morgantown, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Morgantown clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Obesity Clinical Trial in Morgantown, WV

About This Obesity Study in Morgantown

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of MASLD/metabolic dysfunction-associated steatohepatitis (MASH) due to its efficacy in inducing weight loss. Nevertheless, its adoption has been hindered by the perceived invasiveness of surgery. Over the past decade, endoscopic sleeve gastroplasty (ESG) has gained recognition as a promising minimally-invasive approach to weight loss. The procedure involves utilizing a Food and Drug Administration (FDA)-authorized endoscopic suturing device to reduce the gastric volume by 70%. Studies reveal that ESG is associated with approximately 18.2% weight loss at one year after the procedure, with sustained results for at least 10 years. Nevertheless, the effect of ESG on MASH remains unknown. In this study, the investigators will compare ESG + lifestyle modification versus lifestyle modification alone in treating histologic MASH. The study will randomize patients to one of two different treatment options: ESG + lifestyle modification or lifestyle modification alone.

Sponsor: Pichamol Jirapinyo, MD, MPH

Who Can Participate

Inclusion Criteria

Age ≥ 18 (male or female)

BMI ≥30 kg/m2 or ≥27 kg/m2 with at least one obesity-related comorbidity

Self-reported stable weight (no weight change \>5%) for 6 months prior to the first study visit

Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing laboratory/imaging/additional tests, and completing diet counseling

Willingness to NOT start a new anti-obesity medication for the following 12 months

Residing within a reasonable distance from the investigator's office and able to travel to the investigator to complete routine follow-up visits

Ability to give informed consent

Women of childbearing potential (i.e., not post-menopausal, nor surgically sterilized) must agree to use adequate birth control methods

Exclusion Criteria

Known history of other chronic liver diseases (viral hepatitis, autoimmune hepatitis, drug-induced hepatitis, and genetic)

Treatment with vitamin E (at doses ≥800 IU/day), pioglitazone, obeticholic acid, or resmetirom \<90 days before the first study visit

History of foregut or gastrointestinal (GI) surgery (except uncomplicated fundoplication, cholecystectomy or appendectomy)

Prior bariatric surgery

Prior endoscopic sleeve gastroplasty

Any inflammatory disease of the GI tract, including severe (LA Grade C or D) esophagitis, Barrett's esophagus with dysplasia, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease

Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses

Severe gastroesophageal reflux disease (GERD)

A structural abnormality in the esophagus or pharynx, such as a stricture or diverticulum, that could impede passage of the endoscope.

Achalasia or any other severe esophageal motility disorder

Chronic abdominal pain

Gastroparesis or intractable constipation

Hepatic insufficiency or cirrhosis

Severe coagulopathy

Insulin-dependent diabetes (either type 1 or type 2) or a significant likelihood of requiring insulin treatment in the following 12 months or HgbA1C ≥ 12%

Patients on an anti-platelet agent, anticoagulant agent or chronic/routine use of NSAIDs

Patients on corticosteroids, immunosuppressants, or narcotics

Patients on an anti-seizure or anti-arrhythmic medication

Patients who are pregnant or breastfeeding

Excessive alcohol consumption (\>20 g per day for women; \>30 g per day for men)

Active smoking

History of poorly controlled hypertension, coronary artery disease, congestive heart failure, cardiac arrhythmia

History of respiratory diseases such as chronic obstructive pulmonary disease (COPD) requiring steroids, pneumonia, or cancer

History of autoimmune connective tissue disorder such as lupus, scleroderma or immunocompromised disease

History of active malignancy

History of genetic or hormonal causes for obesity, such as Prader Willi syndrome

History of endocrine disorders affecting weight, such as uncontrolled hypothyroidism

Eating disorders, including night eating syndrome, bulimia, binge eating disorder or compulsive overeating

Active psychological issues preventing participation in a lifestyle modification program as determined by a psychologist

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Morgantown?

Yes, this clinical trial (NCT06138821) has an active research site in Morgantown, WV that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Obesity Treatment Options in Morgantown, WV

If you're searching for obesity treatment options in Morgantown, WV, this clinical trial (NCT06138821) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Morgantown research site is actively enrolling participants for this clinical trial. You'll receive care from experienced obesity specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all obesity clinical trials near you to find additional studies recruiting in your area.

Obesity Clinical Trial in Morgantown, WV

Expert Care in Morgantown

IRB Approved

No-Cost Care

Apply for This Morgantown Location

Why Participate?

Simple Process